<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661775</url>
  </required_header>
  <id_info>
    <org_study_id>RJMAG001</org_study_id>
    <nct_id>NCT03661775</nct_id>
  </id_info>
  <brief_title>Serum Magnesium Level Administration in Severe Pre-eclampsia Obese Pregnancy</brief_title>
  <official_title>Serum Magnesium Level Between Administered Rate of 2 g/hr Versus 2.5 g/hr in Severe Pre-eclampsia Obese Pregnancy, Multicentered Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the magnesium level in difference continuous rate in women who were diagnosed&#xD;
      severe pre-eclampsia obese&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium sulfate is, generally, applied in order to alleviate or to avoid seizures. It can&#xD;
      be administered according to many medical approaches. Nevertheless, at Rajavithi Hospital,&#xD;
      the recommended administration of magnesium sulfate is 4 grams for loading dose in 15&#xD;
      minutes, followed by 2 grams for maintenance dose per hour (Zudpan regimen). The therapeutic&#xD;
      index of magnesium is in the range of 4.8-8.4 mg/dL. After that, the level of magnesium&#xD;
      sulfate will be evaluated every 4 or 6 hours.&#xD;
&#xD;
      At Rajavithi Hospital, there are a lot of patients having pre-eclampsia symptom and many&#xD;
      patients, who were received magnesium sulfate in the treatment, having the level of magnesium&#xD;
      sulfate lower than the therapuetic level and needed to increase the maintenance dose to 2.5&#xD;
      grams/hour. Therefore, this work aims to studying the amount of magnesium sulfate&#xD;
      administered to pregnant woman with pre-eclampsia symptom who possess high body mass index&#xD;
      (BMI), especially for BMI greater than or equal to 30 kg/m2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Factorial 2-by-2 open labeled randomised controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>therapeutic level</measure>
    <time_frame>4 hours after infusion magnesium sulfate</time_frame>
    <description>Serum magnesium level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome of pregnancy</measure>
    <time_frame>24 hours after delivery</time_frame>
    <description>maternal and fetal outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Severe Pre-eclampsia</condition>
  <condition>Magnesium Level</condition>
  <arm_group>
    <arm_group_label>controlled group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate administration</intervention_name>
    <description>controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>controlled group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancy women who have MBI â‰¥ 31kg/m2&#xD;
&#xD;
          -  Pregnancy women who were diagnosed severe pre-eclampsia at gestational age 24 weeks&#xD;
             more.&#xD;
&#xD;
          -  Pregnancy women who were diagnosed eclampsia at gestational age 24 weeks more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy women who were chronic kidney disease or have serum creatinine more than 1.1&#xD;
             mg/dl&#xD;
&#xD;
          -  Pregnancy women who have contraindication to use magnesium sulfate&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

